MK-677 (Ibutamoren) and Bupropion Interaction

Why This Interaction Matters

Bupropion is one of the most commonly prescribed antidepressants in the United States, with over 29 million dispensed prescriptions in 2022 according to ClinCalc Drug Usage Statistics. MK-677 (ibutamoren), a non-peptide ghrelin receptor agonist and growth hormone (GH) secretagogue, has gained widespread use in peptide therapy circles despite lacking FDA approval. When patients on bupropion add ibutamoren, or vice versa, two pharmacologic flags appear: enzyme inhibition overlap and additive seizure-threshold lowering.

No Formal DDI Study Exists

No published clinical trial has directly tested the co-administration of ibutamoren and bupropion in human subjects. The interaction profile must therefore be reconstructed from each drug's individual pharmacology. This is a limitation, but it is the standard approach for investigational compounds that have not undergone full Phase III DDI characterization [1].

Who Is Most Affected

Patients at highest risk from this combination include those with a personal or family history of seizures, individuals with eating disorders (a contraindication for bupropion per its FDA label), and patients with pre-existing insulin resistance or type 2 diabetes. Clinicians prescribing both agents off-label should document the risk-benefit discussion in the chart.

Pharmacokinetic Interaction: CYP2D6 and Beyond

The pharmacokinetic concern centers on CYP2D6. Bupropion and its active metabolite hydroxybupropion are potent inhibitors of CYP2D6, producing inhibition comparable to quinidine in clinical studies [2]. Ibutamoren's full metabolic pathway has not been published in a peer-reviewed CYP phenotyping study, but early investigational data from Merck (the original developer) suggest hepatic metabolism involving multiple CYP isoforms.

Bupropion as a CYP2D6 Inhibitor

A single 150-mg dose of bupropion increased the AUC of desipramine (a CYP2D6 substrate) by approximately 200% in a pharmacokinetic study of healthy volunteers [2]. The FDA classifies bupropion as a "strong" CYP2D6 inhibitor. If ibutamoren is partially cleared through CYP2D6, co-administration with bupropion could increase ibutamoren plasma concentrations, prolonging its GH-stimulating and glucose-raising effects.

What We Know About Ibutamoren Metabolism

Ibutamoren (MK-677) has an oral bioavailability near 100% and a terminal half-life of approximately 6 hours, with IGF-1 elevation persisting for up to 24 hours after a single 25-mg dose [3]. The compound undergoes hepatic metabolism, but Merck did not publish a comprehensive in vitro CYP reaction phenotyping study in the peer-reviewed literature. Animal data suggest involvement of CYP3A4, though the relative contribution of CYP2D6 remains uncharacterized [1].

Clinical Implication

Without definitive CYP phenotyping data, clinicians cannot rule out a meaningful pharmacokinetic interaction. The conservative approach: assume that bupropion may modestly increase ibutamoren exposure. Start ibutamoren at the lower end of the dose range (10 mg rather than 25 mg) and titrate based on IGF-1 response and tolerability.

Pharmacodynamic Interaction: Seizure Threshold

This is the more pressing clinical concern. Both drugs have documented associations with lowered seizure threshold, and their effects are additive.

Bupropion and Seizures

Bupropion's seizure risk is dose-dependent. The FDA label reports an incidence of approximately 0.4% (4 per 1,000) at doses up to 450 mg/day for the immediate-release formulation [4]. At doses above 450 mg/day, the risk rises sharply. This dose-dependence prompted the 450 mg/day ceiling that remains in effect across all formulations (IR, SR, XL). Risk factors that compound this baseline include concurrent use of drugs that lower seizure threshold, abrupt discontinuation of benzodiazepines or alcohol, and a history of head trauma.

Ibutamoren and Seizures

Ibutamoren's seizure signal is less well-defined but not absent. In a 2-year randomized trial (N=292) of ibutamoren 25 mg/day in elderly adults with hip fracture, published in the Journal of Clinical Endocrinology & Metabolism, one case of new-onset seizure was reported in the treatment arm versus none in placebo [5]. A separate 12-month study by Nass et al. (N=65, healthy older adults) reported no seizures but did note increased somnolence and lower-extremity edema, both of which can be secondary markers of CNS-active compounds [6]. Growth hormone itself has been associated with reduced GABA-ergic inhibition in animal models, providing a plausible biological mechanism for lowered seizure threshold at supraphysiologic GH levels [7].

Additive Risk Assessment

The combined risk is theoretical but directionally consistent. When a patient takes a strong CYP2D6 inhibitor alongside a CNS-active compound with any seizure signal, the FDA's drug interaction guidance recommends treating the combination as at least moderate risk until formal data become available.

Blood Glucose and Metabolic Effects

Ibutamoren's most consistent adverse effect is elevation of fasting blood glucose. This is a GH-mediated, dose-dependent phenomenon, and bupropion does not attenuate it.

Ibutamoren Raises Glucose

In the key MK-677 study by Nass et al. (2008), ibutamoren 25 mg/day for 12 months increased fasting blood glucose by approximately 0.3 mmol/L (5.4 mg/dL) compared with placebo. HbA1c rose from a mean of 5.5% to 5.7% in the treatment group, crossing the ADA's pre-diabetes threshold of 5.7% [6]. A two-year study in elderly hip-fracture patients confirmed these findings: fasting glucose increased in the ibutamoren group, and two patients developed diabetes requiring treatment versus none in the placebo arm [5].

Bupropion's Metabolic Profile

Bupropion is weight-neutral to mildly weight-reducing, a factor that often drives its selection in patients with obesity or metabolic syndrome. The CONTRAVE combination (naltrexone-bupropion) received FDA approval for chronic weight management based on the COR-I trial (N=1,742), which showed 6.1% mean weight loss versus 1.3% with placebo at 56 weeks [8]. Bupropion alone does not raise fasting glucose. It does not counteract ibutamoren's glucose-raising effect either.

Monitoring Protocol

For patients taking both agents:

• Check fasting glucose and HbA1c at baseline, 6 weeks, and every 3 months thereafter.
• If HbA1c reaches 5.7% or fasting glucose exceeds 100 mg/dL, consider reducing ibutamoren dose or adding metformin per ADA Standards of Care [9].
• Document whether the patient has pre-existing risk factors for type 2 diabetes (BMI ≥ 25, first-degree family history, PCOS, history of gestational diabetes).

Prolactin and Hormonal Considerations

Ibutamoren transiently increases prolactin. In the Nass et al. Study, prolactin rose by approximately 23% within the first 2 weeks of dosing but returned to baseline by week 8 [6]. Bupropion, as a dopamine-norepinephrine reuptake inhibitor, tends to reduce or maintain prolactin levels, since dopamine is the primary prolactin-inhibitory factor. The net effect of co-administration on prolactin is uncertain but likely attenuated compared with ibutamoren alone.

When to Check Prolactin

Routine prolactin monitoring is not necessary for this combination unless the patient reports galactorrhea, menstrual irregularity, or sexual dysfunction. If prolactin is elevated, it is more likely attributable to ibutamoren than bupropion.

Practical Dosing Recommendations

No guideline body has issued formal dosing recommendations for this combination. The following are evidence-informed suggestions based on each drug's pharmacology.

Starting and Titrating Ibutamoren

If a patient is already stable on bupropion (any formulation), start ibutamoren at 10 mg/day rather than 25 mg. Assess tolerability, fasting glucose, and IGF-1 at 4 to 6 weeks. If IGF-1 response is suboptimal and glucose remains below 100 mg/dL, titrate to 15 mg, then 20 mg, then 25 mg at 4-week intervals. Avoid the 25-mg starting dose that most peptide clinics use as default.

Bupropion Dose Considerations

Do not exceed bupropion 300 mg/day (XL) or 400 mg/day (SR) when combining with ibutamoren. The 450 mg/day ceiling applies universally, but the additional seizure-threshold concern from ibutamoren makes the lower end of the dosing range preferable. If the patient requires 450 mg/day of bupropion for depression control, ibutamoren should be used only after explicit seizure-risk counseling and documentation.

Timing of Administration

Ibutamoren is typically taken at bedtime because GH secretion peaks during slow-wave sleep. Bupropion XL is taken in the morning. This natural temporal separation may reduce peak-level overlap, though the clinical relevance of timing separation for this pair is unproven.

Patient Counseling Points

Patients combining these agents need clear instructions on three topics.

Seizure Warning Signs

Any patient taking bupropion should already know seizure warning signs: sudden confusion, uncontrolled jerking movements, staring spells, loss of consciousness. Adding ibutamoren does not change the symptom profile but may change the probability. Patients should be told that the combination has not been formally studied and that prompt reporting of any neurological symptom is required.

Blood Sugar Symptoms

Ibutamoren-induced hyperglycemia is usually asymptomatic in the mild range. Patients should nonetheless be aware of polyuria, polydipsia, and blurred vision as signs of clinically significant glucose elevation. This applies especially to patients with BMI ≥ 30 or those on concurrent corticosteroids.

Edema and Fluid Retention

Ibutamoren causes peripheral edema in approximately 10 to 15% of users, driven by GH-mediated sodium and water retention [5]. Bupropion does not cause edema. Patients should report ankle swelling, rapid weight gain (more than 2 kg in one week), or shortness of breath. The edema typically resolves with dose reduction.

Regulatory Status and Risk Acceptance

MK-677 (ibutamoren) has never received FDA approval for any indication. Merck discontinued its development program after Phase II trials did not meet primary endpoints for osteoporosis and growth hormone deficiency in elderly populations [5]. The compound is currently available through research chemical suppliers and compounding pharmacies, but it is not an FDA-approved drug, an FDA-approved investigational drug under IND, or a legal dietary supplement.

Bupropion, by contrast, has a well-characterized safety profile spanning decades. It is FDA-approved under multiple brand names (Wellbutrin, Zyban, Aplenzin) and in combination with naltrexone (Contrave).

The Endocrine Society's 2019 clinical practice guideline on GH use in adults does not endorse ibutamoren as a GH replacement strategy and explicitly notes that GH secretagogues have not demonstrated long-term safety in adequately powered trials [10].

Prescribers who choose to use ibutamoren off-label with bupropion assume responsibility for a combination that lacks formal DDI data, involves a non-FDA-approved compound, and carries additive seizure-threshold and metabolic risks.